El Dr. Alejandro Recio Mayoral pone en valor la participación de especialistas españoles en esta edición del Heart Failure Congress, con un resumen de las comunicaciones presentadas en la primera jornada del encuentro.

1. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Dr. Alejandro Recio Mayoral
Unidad Insuficiencia Cardiaca Especializada
Unidad Multidisciplinar Hipertensión Pulmonar
Hospital Virgen Macarena
Sevilla
Comunicaciones españolas
presentadas en HF 2021

2. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Empagliflozin in heart failure with preserved ejection
fraction:
decoding its molecular mechanism of action using artificial intelligence
Iborra-Egea O, PhD, Bayes-Genis A, MD PhD; Spitaleri G, MD; Domingo M, MD PhD; Revuelta-López E, PhD; Codina P, MD,
Cediel G, MD PhD; Santiago-Vacas E, MD PhD; Cserkóová A, Pascual-Figal D, MD PhD, Núñez J, MD PhD; Lupón J, MD PhD.
Instituto de Investigación Germans Trias i Pujol
Oriol Iborra-Egea´s presentation HF 2021
Empagliflozin can play a crucial role in
HFrEF, independent of the glycemic
status of the patient.

3. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Introduction
Can Empagliflozin benefit HFpEF patients?
1. Differentiated mechanism from current
failed treatments?
2. Cardiac-specific mechanism of action?
By using AI techniques
Iborra-Egea O et al. Sci Rep. 2021 Jun 8;11(1):12025 Oriol Iborra-Egea´s presentation HF 2021
N= 148 proteins N= 32 proteins
>320,000
interactions

4. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Results:
Mechanism of action and clinical validation
250 possible solutions
1 prominent solution with
94% ANN Accuracy
−14%
Baseline: 290 ± 106 pg/mL 12
months: 249 ± 102 pg/mL
Baseline: 299 ± 70 pg/mL
12 months: 281 ± 67 pg/mL
−6%
Baseline: 313 ± 27 pg/mL
12 months: 259 ± 17 pg/mL
−17%
N=15
Iborra-Egea O et al. Sci Rep. 2021 Jun 8;11(1):12025
NHE1
Oriol Iborra-Egea´s presentation HF 2021

5. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Using AI modelling, we identified that the
main effect of empagliflozin in HFpEF
treatment is exerted via NHE1 and is focused
on cardiomyocyte oxidative stress
modulation. These results support the potential
use of empagliflozin in HFpEF.
Oriol Iborra-Egea´s presentation HF 2021

6. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
JM García Pinilla´s presentation HF 2021
Prevalence of ATTR cardiac amyloidosis among HFpEF

7. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
JM García Pinilla´s presentation HF 2021
13.7% (25/183) had a positive grade 2-3 scintigraphy in
absence of monoclonal proteins
• Age 79.7 years
• Female 48,5%
• Hypertension 88.5%
• Diabetes 42.1%
• NYHA II 61.6%
• LVEF 60.7%
• Septal Maximal Wall thickness 14mm

8. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
JM García Pinilla´s presentation HF 2021
Results

9. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Patricia Palau´s presentation HF 2021
Iron Deficiency and Short-term Adverse Events in
Patients with Decompensated Heart Failure
Patricia Palau MDa*, Pau Llàcer MDb*, Eloy Domínguez MDc, Juan Pablo Tormo MDc, Rim Zakarnec, Anna Mollara, Ana Martíneza, Gema Miñana
MDa, Enrique Santas MDa, Rafael De La Espriella MDa, Eduardo Núñez MDa, Luis Manzano MDb, Antoni Bayés-Genís MDd,e, Julio Núñez MDa,e
a Servicio de Cardiología, Hospital Clínico Universitario. INCLIVA. Universitat de València. Valencia-Spain; b Servicio de Medicina Interna. Hospital Universitario Ramón y Cajal.
Madrid-Spain.; c FISABIO, Universitat Jaume I, Castellón-Spain. dInstitut del Cor, Hospital Universitari Germans Trias i Pujol, Badalona. Universitat Autònoma de Barcelona
Spain. eCIBER Cardiovascular. Madrid-Spain
This study aimed to evaluate the value of the utility of transferrin
saturation (TSAT) or serum ferritin to predict the risk of 30-day
readmission for HF or death in patients with DHF.

10. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Patricia Palau´s presentation HF 2021
Methods
• Retrospective multicenter registry study
• 1701 ADHF patients
• Serum ferritin and transferrin saturation were evaluated 24-72 h after hospital admission

11. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Patricia Palau´s presentation HF 2021
Results
• Age 76 (68-82) years, 43.8% were women
• Left ventricular ejection fraction >50%, 51.7%
• NT-proBNP 4067 pg/mL (1900–8764)
• Ferritin 102 ug/L (54-203)
• TSAT 14.1% (9-20.3)
TSAT <20% identified patients with worse baseline risk profile (greater CV risk factors, comorbidities)
Covariates included in the final multivariate model were: age, sex, last New York Heart Association (NYHA) functional
class III/IV under stable conditions, prior admission for DHF, dyslipidemia, Charlson Comorbidity index, systolic blood
pressure, heart rate, atrial fibrillation, left ventricular ejection fraction (LVEF), left atrial diameter,hemoglobin, glomerular
filtration rate, and NT-proBNP.
Conclusion
Lower TSAT, but not ferritin, was
associated with a higher risk of short-
term events in patients with DHF
Transferrin saturation, % Serum Ferritin levels, ug/l

12. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Estefanía Tarazón´s presentation HF 2021

13. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Estefanía Tarazón´s presentation HF 2021
Background and porpouse
Contribution of sphingolipids in heart failure

14. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Estefanía Tarazón´s presentation HF 2021
Methods

15. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Estefanía Tarazón´s presentation HF 2021
Results
Conclusions

16. Alejandro Recio Mayoral
Comunicaciones españolas en HF 2021
Enhorabuena
a todos!!